Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.

International Journal of Molecular Sciences
Kenichi Miyamoto, Yosuke Minami

Abstract

Recently, whole exome sequencing for acute myeloid leukemia (AML) has been performed by a next-generation sequencer in several studies. It has been revealed that a few gene mutations are identified per AML patient. Some of these mutations are actionable mutations that affect the response to an approved targeted treatment that is available for off-label treatment or that is available in clinical trials. The era of precision medicine for AML has arrived, and it is extremely important to detect actionable mutations relevant to treatment decision-making. However, the percentage of actionable mutations found in AML is about 50% at present, and therapeutic development is also needed for AML patients without actionable mutations. In contrast, the newly approved drugs are less toxic than conventional intensive chemotherapy and can be combined with low-intensity treatments. These combination therapies can contribute to the improvement of prognosis, especially in elderly AML patients who account for more than half of all AML patients. Thus, the treatment strategy for leukemia is changing drastically and showing rapid progress. In this review, we present the latest information regarding the recent development of treatment for AML.

References

Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·D SmallA M Gewirtz
Dec 1, 2000·Nature·B VogelsteinA J Levine
Nov 13, 2001·Oncogene·T D ZhangZ Chen
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith E KarpKenneth S Bauer
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Dec 22, 2006·European Journal of Clinical Investigation·A W HauswirthP Valent
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith E KarpA Dimitri Colevas
Jan 18, 2008·Leukemia·J Pedersen-BjergaardD H Christiansen
Jan 31, 2008·Leukemia & Lymphoma·Lillian P Burke, Cynthia A Kukoly
Apr 11, 2009·Nature·Teresa A SoucySteven P Langston
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
Apr 25, 2013·International Journal of Hematology·Michael R Grunwald, Mark J Levis
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jul 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·David S RitchieH Miles Prince
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis

❮ Previous
Next ❯

Citations

Mar 12, 2021·Frontiers in Oncology·Christian Récher

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
MDS
histone acetylation
acetylation

Clinical Trials Mentioned

NCT03258931
NCT03836209
NCT02236013
NCT02927262
NCT02997202
NCT03839771
NCT03173248
NCT03072043
NCT03381781
NCT03560882

Software Mentioned

BiTE

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.